Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib-Reference-Cited by-同舟云学术

Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib

Published:2019-05 Issue:3 Volume:57 Page:290-291
ISSN:2212-5345
Container-title:Respiratory Investigation
language:en
Short-container-title:Respiratory Investigation

Author:

Bergantini Laura,Bargagli Elena,Cameli Paolo,Cekorja Behar,Lanzarone Nicola,Pianigiani Lucrezia,Vietri Lucia,Bennett David,Sestini Piersante,Rottoli Paola^ORCID

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference5 articles.

1. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis;Wakamatsu;Respir Investig,2017

2. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am J Respir Crit Care Med,2011

3. Standardisation of spirometry;Miller;Eur Respir J,2005

4. Baseline KL-6 predict increased risk acute exacerbation idiopathic pulmonary fibrosis;Ohshimo;Respir Med,2014

5. Sputum biomarkers in IPF: evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7;Guiot;PLoS One,2017

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease;Tissue and Cell;2024-10

2. State of the Globe: A Glimmer of Hope – Biomarkers for Diagnosing COVID-19 Pulmonary Fibrosis;Journal of Global Infectious Diseases;2024-04

3. Predictive ability of longitudinal changes in Kerbs von Lungren 6 for acute exacerbation of fibrotic interstitial lung disease: Database research;2024-02-28

4. Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone;Biomedicines;2024-02-08

5. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases;Respiration;2023